For the Inventor, By the Inventor

Enter assignee name

Novato, CA, United States of America

Biomarin Pharmaceutical Inc.

USPTO Granted Patents = 136

CIPO Patents = 11

EPO Patents = 44

Trademarks = 24

Forward Citations = 1,116

Loading Chart...

Loading Chart...

141 inventors (with patents filed for the assignee):

Augustus O Okhamafe (23 out of 29 patents)

Daniel J Wendt (23 out of 23 patents)

Emil D Kakkis (21 out of 44 patents)

4. Jonathan LeBowitz (18 out of 23 patents)

5. Michel Claude Vellard (16 out of 16 patents)

6. Bing Wang (13 out of 64 patents)

7. James R Rusche (13 out of 18 patents)

8. Brett E Crawford (13 out of 15 patents)

9. Charles A Glass (13 out of 19 patents)

10. Mika Aoyagi-Scharber (12 out of 12 patents)

11. Jillian R Brown (12 out of 14 patents)

12. Vincent Jacques (11 out of 29 patents)

13. Shinong Long (11 out of 11 patents)

14. Norton P Peet (11 out of 87 patents)

15. Melita Dvorak-Ewell (10 out of 10 patents)

Core Competencies:

Adeno-Associated Virus

C-Type Natriuretic Peptide

Lysosomal Enzymes

Phenylalanine Ammonia-Lyase

Histone Deacetylase Inhibitors

Therapeutic Proteins

Glucosylceramide Synthase Inhibitors

Skeletal Dysplasia

Osteoarthritis

CLN2 Disease

Targeted Therapeutics

136 patents: Sort by Forward Citations

1. 12514906 - Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia (2026-01-06),

2. 12239692 - Adeno-associated virus factor VIII vectors (2025-03-04),

3. 12233106 - C-type natriuretic peptide variants to treat skeletal dysplasia in children (2025-02-25),

4. 12214015 - Use of c-type natriuretic peptide variants to treat osteoarthritis (2025-02-04),

5. 12188058 - Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof (2025-01-07),

6. 12076372 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2024-09-03),

7. 11918633 - Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects (2024-03-05),

8. 11911446 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2024-02-27),

9. 11821008 - Liver targeting adeno-associated viral vectors (2023-11-21),

10. 11739345 - Methods of treating phenylketonuria (2023-08-29),

11. 11690898 - Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same (2023-07-04),

12. 11590204 - Use of C-type natriuretic peptide variants to treat skeletal dysplasia (2023-02-28),

13. 11584780 - Adeno-associated virus capsid proteins (2023-02-21),

14. 11505790 - Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof (2022-11-22),

15. 11406690 - Adeno-associated virus factor VIII vectors (2022-08-09),

BioMarin Pharmaceutical Inc. is a global biotechnology company that develops and markets innovative therapies for patients with serious and life-threatening rare genetic diseases. With a focus on developing groundbreaking treatments in areas of high unmet medical need, BioMarin strives to improve the lives of patients and families affected by these rare diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 13 2026

136 Patents

#1 in Novato, CA

#638 in California

#2,750 in US

#5,794 in the World

Novato, CA, United States of America

Biomarin Pharmaceutical Inc.

Forward Citations = 1,116

141 inventors:

Augustus O Okhamafe (23 out of 29 patents)

Daniel J Wendt (23 out of 23 patents)

Emil D Kakkis (21 out of 44 patents)

4. Jonathan LeBowitz (18 out of 23 patents)

5. Michel Claude Vellard (16 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…